Biophytis (EPA:ALBPS) | WebDisclosure

Basculer en Français

9805	Companies
196647	Keywords
127661	Articles
104550	Press releases

Home
Companies
Biophytis

REGULATED PRESS RELEASE

published on 09/15/2025 at 07:00, 4 months 19 days ago

Biophytis Secures public funding in Brazil for Obesity Phase 2 Trial and Signs Agreements with Leading local Clinical Partners
Biophytis secures public funding in Brazil for Obesity Phase 2 trial and signs agreements with leading local clinical partners, strengthening its OBA Phase 2 program and obtaining non-dilutive funding support through EMBRAPII

Biophytis Public Funding EMBRAPII Obesity Phase 2 Trial Clinical Partners
REGULATED PRESS RELEASE

published on 09/15/2025 at 07:00, 4 months 19 days ago

Biophytis obtient un financement public au Brésil pour l’essai de Phase 2 dans l’obésité et signe des accords avec des centres cliniques locaux de premier plan
Biophytis obtient un financement public et signe des accords pour l'essai de Phase 2 dans l'obésité au Brésil, renforçant ainsi son programme et sa valeur pour les investisseurs

Biophytis Brésil Phase 2 Obésité Financement Public
BRIEF

published on 09/11/2025 at 07:05, 4 months 23 days ago

Biophytis Announces Phase 3 Sarcopenia Trial for BIO101 in Europe and Asia

Age-related Diseases BIO101 Sarcopenia Clinical Trial Biophytis Strategy Asia And Europe
BRIEF

published on 09/11/2025 at 07:05, 4 months 23 days ago

Biophytis Lance un Essai de Phase 3 sur la Sarcopénie avec BIO101

Biophytis Essai Clinique Sarcopénie BIO101 Europe Et Asie
REGULATED PRESS RELEASE

published on 09/11/2025 at 07:00, 4 months 23 days ago

Biophytis unveils Phase 3 Sarcopenia Trial Strategy with BIO101 in Europe and Asia
Biophytis announces Phase 3 Sarcopenia Trial Strategy with BIO101 targeting age-related sarcopenia in Europe and Asia, aiming to address a significant unmet medical need and commercial market

Biophytis Clinical Trial Sarcopenia Phase 3 BIO101
REGULATED PRESS RELEASE

published on 09/11/2025 at 07:00, 4 months 23 days ago

Biophytis dévoile sa stratégie d’essai de phase 3 dans la sarcopénie avec BIO101 en Europe et en Asie
Biophytis annonce sa stratégie d'essai de phase 3 pour la sarcopénie avec BIO101 en Europe et en Asie, ciblant un marché médical important et non satisfait

Biophytis Europe Asie Sarcopénie Phase 3
PRESS RELEASE

published on 09/11/2025 at 06:59, 4 months 23 days ago

Biophytis dévoile sa stratégie d’essai de phase 3 dans la sarcopénie avec BIO101 en Europe et en Asie
Biophytis présente sa stratégie d'essai de phase 3 pour la sarcopénie avec BIO101 en Europe et Asie, visant à devenir pionnier dans ce domaine thérapeutique en croissance rapide

Biophytis Essai Clinique Sarcopénie Phase 3 BIO101
BRIEF

published on 09/03/2025 at 07:05, 5 months 1 day ago

Biophytis obtient l'approbation de l'EMA pour une étude clinique phase 2 sur l'obésité

Biophytis Essai Clinique Phase 2 Obésité EMA
BRIEF

published on 09/03/2025 at 07:05, 5 months 1 day ago

Biophytis Advances Obesity Treatment with EMA Approval

Biophytis Obesity Treatment Clinical Trial BIO101 EMA Authorization
REGULATED PRESS RELEASE

published on 09/03/2025 at 07:00, 5 months 1 day ago

Biophytis obtient l'autorisation de l'EMA pour le lancement de son étude clinique de phase 2 dans l’obésité
Biophytis obtient l'autorisation de l'EMA pour lancer l'étude clinique de phase 2 sur l'obésité en Europe et prépare le recrutement des patients. La société se réjouit de cette avancée réglementaire cruciale

Biophytis Étude Clinique Obésité Autorisation EMA

Accesswire

Published on 02/05/2026 at 01:35, 4 hours 36 minutes ago

Dr. Ruben Shiffman Files Early Warning Report in Respect of Greenland Resources
Published on 02/05/2026 at 00:00, 6 hours 11 minutes ago

Onco-Innovations Announces Filing of Preliminary Base Shelf Prospectus
Published on 02/04/2026 at 22:25, 7 hours 46 minutes ago

55 North Mining Announces Flow-Through Financing
Published on 02/04/2026 at 18:00, 12 hours 11 minutes ago

Lithium South AGSM Update
Published on 02/04/2026 at 16:15, 13 hours 56 minutes ago

Trans Canada Gold Enters into an Option Agreement with Bear Mountain Gold Mines to Acquire a 60% Interest in the Harrison Lake District Scale Gold Property, with $10.0 Million Dollars in Prior Exploration Expenditures

View all ACCESSWIRE

EQS Group

Published on 02/04/2026 at 20:54, 9 hours 17 minutes ago

Elmos Semiconductor SE is planning to distribute 36 million Euro to shareholders for the fiscal year 2025
Published on 02/04/2026 at 20:36, 9 hours 35 minutes ago

EQS-Adhoc: Elmos Semiconductor SE approves share buyback program via the stock exchange of 10 million Euro and dividend proposal of 1.50 Euro per share for fiscal year 2025
Published on 02/04/2026 at 20:00, 10 hours 11 minutes ago

Belgium's Ingmar De Vos elected to Executive Board of International Olympic Committee
Published on 02/04/2026 at 18:55, 11 hours 16 minutes ago

Funding Circle Holdings plc: POS-Transaction in Own Shares
Published on 02/04/2026 at 18:40, 11 hours 31 minutes ago

Robin Zeng: Unlocking the Sustainable Energy Era with Zero-Carbon Technology

Les Echos

Published on 02/04/2026 at 18:04, 12 hours 7 minutes ago

Capital et droits de vote au 31 janvier 2026
Published on 02/04/2026 at 18:04, 12 hours 7 minutes ago

Total number of voting rights and shares making up the share capital at January 31, 2026
Published on 02/04/2026 at 17:45, 12 hours 26 minutes ago

Information concerning the total number of voting rights and shares 2026 01 31
Published on 02/04/2026 at 17:45, 12 hours 26 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 02/04/2026 at 17:45, 12 hours 26 minutes ago

Janvier 2026

View all LES ECHOS COMFI WIRE